Israel's Teva Pharmaceutical Industries has posted another strong set of financials for the third quarter, with net income rising 21% to $637 million, or $0.77 per share (+20%).

Sales rose 20% to $2.84 billion, helped by sales of Teva’s generic versions of GlaxoSmithKline’s antiepileptic Lamictal (lamotrigine), the antidepressant Wellbutrin XL (extended-release bupropion) and Johnson & Johnson’s antipsychotic Risperdal (risperidone) launched in the last two quarters. The firm’s copycat versions of Novartis’ blood-pressure-lowering treatment Lotrel (almodipine/benazepril).

Teva noted that as of October 28, it had 145 product applications awaiting final US Food and Drug Administration approval. The company believes it will be the first to file on 58 of these, relating to products whose annual US branded sales are worth $42 billion. In Europe, Teva has 203 compounds pending submission in 402 formulations.

The company’s branded business was again dominated by Copaxone (glatiramer acetate). The multiple sclerosis treatment brought in $562 million, an increase of 28%, helped by strong growth both in and outside the USA. Sales of Azilect (rasagiline) for Parkinson’s disease reached $46 million, up 38%, while global respiratory revenues were flat at $177 million.

Chief executive Shlomo Yanai said Teva had enjoyed “an intensive and exciting quarter”, which saw the firm enter into a new strategic partnership in Japan with Kowa, close the acquisition of Bentley in Spain and secure the necessary financing for the $7.46 billion purchase of Barr Pharmaceuticals. That deal is expected to close by the end of this year, he added.